This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts’ Opinions Are Mixed on These Healthcare Stocks: BrightSpring Health Services, Inc. (BTSG), AbbVie (ABBV) and Novo Nordisk (NVO)

Tipranks - Tipranks - Tue Aug 4, 6:46AM CDT

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on BrightSpring Health Services, Inc. (BTSG), AbbVie (ABBV) and Novo Nordisk (NVO).

Claim 55% Off TipRanks

BrightSpring Health Services, Inc. (BTSG)

BTIG analyst David Larsen maintained a Buy rating on BrightSpring Health Services, Inc. today and set a price target of $90.00. The company’s shares closed last Friday at $59.71.

According to TipRanks.com, Larsen has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -5.4% and a 34.2% success rate. Larsen covers the Healthcare sector, focusing on stocks such as Definitive Healthcare Corp, Lifestance Health Group, and Oncology Institute. ;'>

BrightSpring Health Services, Inc. has an analyst consensus of Strong Buy, with a price target consensus of $78.00, implying a 12.3% upside from current levels. In a report issued on July 31, TipRanks – PerPlexity also upgraded the stock to Buy with a $83.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

AbbVie (ABBV)

Wells Fargo analyst Mohit Bansal maintained a Buy rating on AbbVie today and set a price target of $295.00. The company’s shares closed last Friday at $250.94.

According to TipRanks.com, Bansal is a 5-star analyst with an average return of 10.4% and a 58.1% success rate. Bansal covers the Healthcare sector, focusing on stocks such as Milestone Pharmaceuticals, BioMarin Pharmaceutical, and Vertex Pharmaceuticals. ;'>

AbbVie has an analyst consensus of Strong Buy, with a price target consensus of $272.95, an 8.1% upside from current levels. In a report issued on July 20, TipRanks – Google also upgraded the stock to Buy with a $281.00 price target.

Novo Nordisk (NVO)

BMO Capital analyst Evan Seigerman reiterated a Hold rating on Novo Nordisk today and set a price target of $45.00. The company’s shares closed last Friday at $47.08.

According to TipRanks.com, Seigerman is a 4-star analyst with an average return of 7.4% and a 55.5% success rate. Seigerman covers the Healthcare sector, focusing on stocks such as Structure Therapeutics, Inc. Sponsored ADR, NewAmsterdam Pharma Company, and Vertex Pharmaceuticals. ;'>

Currently, the analyst consensus on Novo Nordisk is a Hold with an average price target of $44.67, implying a -5.8% downside from current levels. In a report issued on August 1, TipRanks – PerPlexity also downgraded the stock to Hold with a $50.00 price target.

Read More on BTSG:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).